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Abstract
Objectives—The purpose of this study was to determine the demographic and pharmacogenetic 
covariates that influence the disposition of efavirenz (EFV) and its major metabolites. Methods: A 
population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-
interaction study in healthy male Korean subjects (n=17). Plasma concentrations of EFV and its 
hydroxy-metabolites (0–120 hrs) were measured by LC/MS/MS. Genomic DNA was genotyped 
for variants in the cytochrome P450 (CYP) 2A6, 2B6, 3A5 and MDR1 genes. A PK model was 
built in a stepwise procedure using nonlinear mixed effect modeling in NONMEM 7. The 
covariate model was built using the generalized additive modeling and forward selection-
backward elimination. Model-based simulations were performed to predict EFV steady-state 
concentrations following 200, 400, and 600 mg daily oral dose among different CYP2B6 
genotypes
Results—The final model included only CYP2B6 genotype as covariate that predicts EFV 
clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance. 
The total clearance of EFV in CYP2B6*6/*6 genotype was ~ 30% lower than CYP2B6*1/*1 or 
CYP2B6*1/*6 alleles (P<0.001). Clopidogrel reduced both formation and elimination clearances 
of 8-OH EFV by 22% and 19% respectively (P= 0.033 and 0.041). Other demographics and 
genotype of accessory CYP pathways did not predict EFV or metabolites PK.
Conclusion—CYP2B6 genotype was the only significant predictor of EFV disposition. The 
developed model may serve as the foundation for further exploration of pharmacogenetic-based 
dosing of EFV.
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INTRODUCTION
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in 
combination with 2 NRTs as a first line treatment of human immunodeficiency virus (HIV) 
type 1 infection in treatment naïve patients. Despite favorable antiviral efficacy, clinical 
response and adverse effects of EFV varies widely among individuals. Efavirenz has a 
narrow therapeutic range at steady-state, with some investigators recommending between 1 
to 4 mg/L.1 This along with the considerable between subject variability (BSV) in its 
pharmacokinetics compromises prediction of EFV associated adverse effects and clinical 
outcomes.1–4 Indeed concentrations below 1 mg/L have been associated with an increased 
risk for viral resistance and therapeutic failure, while concentrations above 4 mg/L have 
been associated with an increased risk for the development of central nervous system (CNS) 
toxicity, hepatic toxicity and treatment discontinuation.1 Thus identifying sources of EFV 
pharmacokinetic variability is important to improve therapeutic efficacy while decreasing 
EFV-mediated adverse effects.
Efavirenz is predominantly cleared by hepatic metabolism to pharmacologically inactive 
metabolites, predominantly through cytochrome P450 (CYP) 2B6-mediated 8-hydroxylation 
to 8-hydroxyefavirenz (8-OH EFV).5 Additional enzymes including CYP1A2, CYP2A6, 
and CYP3A4/5 show activity in vitro towards EFV 8-hydroxylation.5,6 Additional minor 
metabolic pathways include EFV hydroxylation to the 7-OH EFV metabolite, mediated by 
CYP2A6,6 and N-glucuronidation mediated by UGT2B7 to EFV N-glucuronide.7 The 
hydroxyl metabolites undergo further metabolism to di-hydroxyl EFV which is also 
catalyzed by CYP2B6 or excreted after conjugation (sulfation and glucuronidation).6,8
The CYP2B6 gene is highly polymorphic, with 38 alleles and multiple sub-alleles and single 
nucleotide polymorphisms identified (http://www.cypalleles.ki.se/cyp2b6.htm; accessed 
October 2013). Among these variants, the CYP2B6*6 allele is the most frequent across 
different populations and is functionally relevant.9,10 Several studies in healthy volunteers 
and HIV patients have demonstrated that this variant is associated with increased EFV 
exposure, higher incidence of CNS and hepatic toxicity as well as treatment 
discontinuation.2,11–15 The contribution of CYP2A6, CYP3A and UGT2B7 and their 
potential impact on the overall pharmacokinetic variability in EFV in vivo seems relatively 
small, with some studies demonstrating an effect while others do not. 6,7,16–20 The inter-
individual variability in EFV pharmacokinetics may also be attributed to differences in the 
ability of EFV to induce its own metabolism, via induction of CYP2B6 and possibly other 
enzymes involved in its metabolism.21–24
The effects of genetics and covariates on the variability of EFV pharmacokinetics and 
exposure have been explored previously.18,25–29 However, there are no reports that 
incorporate the hydroxyl metabolites of EFV into a pharmacogenetic-based covariate 
analysis. Incorporation of the hydroxyl EFV metabolites into a covariate model may 
increase the sensitivity to identify relevant CYP enzymes that contribute to the inter-
individual variability in the pharmacokinetics of EFV and provide mechanistic information 
regarding the in vivo contributions of the enzymes catalyzing efavirenz metabolism. 
Therefore, the objectives of this study were to develop a pharmacogenetic-based 
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pharmacokinetic model that simultaneously describes disposition of EFV and its major 
metabolites as well as characterize the contribution of demographic and pharmacogenomic 
covariates to inter-patient variability in EFV pharmacokinetics.
Consequently, the model based prediction of EFV steady state concentrations were 
generated using this final covariate model among different CYP genotype groups following 
the conventional (600mg) and reduced (200 and 400 mg) EFV dosage regimens. Ultimately, 
adequate prediction of EFV steady-state concentrations from pharmacogenetic information 
may aid in optimizing EFV therapeutic outcomes through managing inter-patient variability 
in its exposure.
METHODS
Study Design
This population pharmacokinetic analysis was performed using data from a randomized 
cross-over drug interaction study of EFV with clopidogrel, and itraconazole in healthy, 
Korean volunteers.30 The study was approved by the Institutional Review Board of Inje 
University Busan Paik Hospital, Korea, and each subject signed a written informed consent. 
Subjects were excluded from the study for any of the following reasons: allergy to EFV, 
intake of prescription or non-prescription medications or herbal supplements for the duration 
of the study, hemoglobin concentration less than 12.5 mg/dl, history of bleeding, 
hematological disorders, in addition to any clinically significant abnormality in the initial 
screening evaluation. Initial screening evaluation included medical history, physical 
examination, routine serum chemistry, and urinalysis test results.
Subjects were administered 75 mg of clopidogrel per day for four days, itraconazole 200 
mg/day for six days, or placebo prior to EFV. A single 200 mg dose of EFV was 
administered orally one hour following the last dose of clopidogel, itraconazole, or placebo. 
Study phases were separated by an 8-week wash out period. A total of 663 venous blood 
samples were obtained from 17 subjects (13 samples per subject per phase) immediately 
before and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24, 48, 72, and 120 hours after EFV 
administration. , Data obtained from the itraconazole phase were not used in this study since 
no interaction was found, as previously reported.30
DNA was extracted from whole blood and genotyping was performed by pyrosequencing 
for functionally important single nucleotide polymorphisms (SNPs) that define CYP2A6 (*4, 
*7, *9 and *15), CYP2B6 (*4, *6 and *9), CYP3A5 (*1 and *3) alleles, and SNPs 
2677G/A/T and 3435C/T in MDR1, as previously reported.30
Drug Assays
Efavirenz and its hydroxyl metabolites (7-OH EFV; 8-OH EFV; and 8,14-OH EFV) were 
extracted after incubation with β-glucuronidase and analyzed by liquid chromatography-
tandem mass spectrometry (LC/MS/MS), as previously reported.30 Samples were analyzed 
in triplicate using an API 3000 LC/MS/MS system (Applied Biosystems, Foster City, USA) 
equipped with an Agilent 1100 series HPLC system (Agilent, Wilmington, DE). 
Chromatographic separation of the compounds was accomplished by use of a Luna C18 
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column (2.0 × 100 mm, 3 μm; Phenomenex, Torrance, CA), with a 20 mM ammonium 
acetate buffer (pH 3.8) and acetonitrile (1:9 [vol]/[vol]) at a flow rate of 0.2 mL/min. EFV 
and metabolite concentrations were obtained. The lower limits of quantification for EFV and 
its metabolites was 3 ng/mL. The inter-assay precision values for all of the samples were 
less than 25%.
Model Development
Population pharmacokinetic analysis was performed using nonlinear mixed-effects modeling 
in NONMEM version 7 (ICON Development Solutions, Ellicott City, MD, USA). The 
ADVAN6 subroutine (general subroutine allows coding of the model differential equations) 
was selected to code for the tested models. First-order conditional estimation (FOCE) with 
interaction was used to estimate the model parameters, within- and between subject 
variability. Evaluated models were discriminated based on the change in the objective 
function value (OFV) and goodness of fit diagnostic plots (individual plots, residual plots, 
and observed versus predicted plasma concentration). Development of the final 
pharmacokinetic model was done in two steps: building the basic structural pharmacokinetic 
model that describes the disposition of EFV and the hydroxyl metabolites; and then selection 
of the significant covariates to be included in the final model.
The structural pharmacokinetic model was built sequentially starting with the EFV and 
followed by the metabolites. One- and two-compartment models with first order elimination 
were compared with several types of absorption profiles for EFV, including direct and 
sequential absorption with and without a lag time. Once the optimal model was selected for 
EFV, the model was expanded to allow for simultaneous modeling of the formed 
metabolites. One- and two-compartment models were evaluated to best describe metabolites 
disposition following first order metabolic transformation based on the proposed metabolic 
pathways. The final structural base model included the parent EFV with the 7-OH and 8-OH 
EFV metabolites. The model would not converge in the presence of the 8,14-OH metabolite 
when all parameters were estimated. A separate model was developed that included the 8-
OH and 8,14-OH EFV metabolites (data not presented).
The effect of clopidogrel on all the described clearances was assessed by including an 
inhibition parameter (INH) as shown in the following equation:
Where θ is the population estimate, CLO represents the study phase with values of 0 in 
control phase or 1 in clopidogrel phase, and η is the between subject variability.
Covariate Model
The structural base model was used to evaluate the potential contribution of individual-
specific covariates to describe the observed variability in the pharmacokinetics of EFV and 
its metabolites. The covariates tested included subject height, weight, and genotypes of 
CYP2A6, CYP2B6, CYP3A5, and MDR1variants. The final covariate model was built in two 
steps. Potential covariates were identified using a generalized additive model (GAM) 
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building approach and followed by stepwise forward selection and backward elimination of 
the covariates using NONMEM. The GAM was performed using XPOSE (ver. 4.3.2) in R 
(ver. 2.11.1). Univariate linear regression was performed on the estimated pharmacokinetic 
parameter estimates with covariates in a stepwise fashion. In each step the covariate that 
resulted in the largest decrease in the Akaike Information Criterion (AIC) was retained in 
the model. The potential covariates that were determined by GAM were then tested in 
NONMEM using the stepwise forward selection and backward elimination approach. In this 
method covariate-parameter relationships were evaluated stepwise (i.e. single covariate and 
single parameter in each step). The covariate that resulted in the greatest statistically 
significant decrease in the OFV was kept in the model and remaining significant covariates 
were added in the same fashion. The ΔOFV follows a chi-square distribution where a change 
of 3.84 (df=1) or 5.99 (df=2) is statistically significant at α = 0.05. A p-value of 0.20 was 
used for the backward elimination procedure. Only one statistically significant covariate 
(CYP2B6) was included in the model.
Model Evaluation
The adequacy of the model fitting was evaluated by individual concentration-time profiles, 
predicted versus observed concentrations and weighted residuals versus predicted 
concentrations. The predictive accuracy of the final model for the observed data was 
evaluated by constructing visual predictive checks (VPC) using R (ver. 2.11.1). The final 
model was used to simulate 1000 hypothetical subjects using the same study design. Plasma 
concentrations of EFV and its 2 metabolites were simulated for 120 hours after oral 
administration of 200mg EFV dose in the absence and the presence of clopidogrel. The 90% 
prediction interval was constructed by plotting the 5th and 95th percentiles of the simulated 
concentration-time profiles.
Pharmacokinetic Simulations
The final covariate pharmacokinetic model was used to perform population simulations in 
NONMEM to predict steady state EFV plasma concentrations under various conditions. 
Efavirenz 600 mg daily is the recommended starting dose, however reduced doses of 200 
and 400 mg daily has demonstrated success in patients that present with high EFV serum 
concentrations.31–33 Steady state EFV plasma concentrations following 200, 400, and 600 
mg daily EFV doses were simulated up to a 8 weeks in each CYP2B6 genotype.
Steady administration of EFV may induce CYP2B6 activity and thereby increase its own 
metabolism and clearance with multiple doses.21,22,34 Therefore, an auto-induction 
component was added to the final model based on the model by Zhu et al.22 The model was 
modified according to the following equation:
Where (CL/FEFV)1 and (CL/F)EFV,SS are EFV clearances at day 1 and steady state 
respectively. AImax is the maximal change of clearance from baseline and T50 is the time to 
reach 50% of the AImax. AImax is represented as (A) ×(CL/FEFV)1, where (A) was the 
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proportionality constant that represents fold change in clearance and it has values of 0, 1.9 or 
2.7 based on the reported change in EFV clearance among different CYP2B6 genotypes; 
CYP2B6*6/*6, CYP2B6*1/*6 and CYP2B6*1/*1 respectively.35
Statistics
Estimated pharmacokinetic parameters were compared between three subgroups categorized 
by CYP2B6 genotype. Normality of the parameters was investigated using the Shapiro-Wilk 
W-test. Normally distributed parameters were compared using a one-way ANOVA test and 
the Kruskal-Wallis test was used for non-normally distributed parameters. When statistically 
significant differences were observed between the subgroups, a post-hoc analysis was 
performed using Bonferroni correction or the nonparametric Mann-Whitney U test. All 
statistical analyses were performed at level of significance of 5%. Statistical analyses were 
performed using PASW statistics 18, release Version 18.0.0 (Ó SPSS, Inc., 2009, Chicago, 
IL).
RESULTS
Seventeen healthy, Korean male subjects completed both study phases and were included in 
the final analysis. Table 1 summarizes the characteristics of study subjects and CYP 
genotype frequencies. CYP2A6 genotypes were categorized into normal, intermediate and 
slow metabolizers according to the reported genotype-predicted functional change.16 The 
same categorization was made for CYP2B6 genotypes, while CYP3A5 were categorized as 
expressers and nonexpressers. The frequency of CYP2A6, CYP2B6, CYP3A5, and ABCB1 
are listed in Table 1. The allelic frequencies were in Hardy-Weinberg equilibrium.
Structural Pharmacokinetic Model Development
A structural pharmacokinetic model was developed that describes the disposition of EFV 
and its major metabolites (7-OH EFV and 8-OH EFV) following oral administration of a 
single 200 mg EFV dose. Efavirenz disposition was characterized by a two compartment 
model following first order absorption incorporating a lag time as illustrated in Figure 1. 
Elimination of EFV from the central compartment was characterized by the first order 
formation of both hydroxyl-metabolites (CLf1/F, CLf2/F) and a first order non-metabolic 
clearance (CLother/F). A one compartment model was sufficient to describe each of the 
hydroxyl-metabolites. The volumes of distribution for the formed metabolites (Vm1 and 
Vm2) were fixed to 10 L. Clearance of both formed metabolites was described by first order 
elimination (CLm1, CLm2). In the presence of clopidogrel, the inhibition parameter was 
estimated in the final model to be 0.78 and 0.81 for both formation and elimination 
clearances of 8-OH EFV respectively (P= 0.033 and 0.041), where it was not statistically 
significantly different from 1 for other clearances.
Covariate Model Development
The covariates that significantly decreased the AIC in the GAM analysis and were 
introduced to the pharmacokinetic model were CYP2A6, CYP2B6 and CYP3A5 genotypes 
as discrete covariates and subject body weight as a continuous covariate. The stepwise 
changes in OFV by the inclusion of the covariates in the structural base model are presented 
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in Supplemental Table 1. The covariates that resulted in statistically significant decreases in 
OFV were: (1) CYP2B6 on CLf2/F; (2) CYP2B6 on INH1; (3) CYP3A5 on CLf2/F; and (4) 
CYP2A6 on CLother/F. The largest decrease in the OFV was observed with CYP2B6 
genotype on CLf2/F and hence this was used as the base model for step 2. None of the other 
covariates had a statistically significant effect in step 2 when CYP2B6 genotype on CLf2/F 
was considered in the model. Therefore, the final model only included CYP2B6 genotype as 
a covariate on CLf2/F.
Table 2 displays the estimated model parameters for the base structural model and the final 
covariate model. Inclusion of CYP2B6 genotype in the covariate model predicted 
approximately 22% of the between subject variability in CLf2/F.
Model Evaluation
The goodness of fit plots showed adequate model prediction of the observed plasma 
concentrations of EFV and its hydroxyl metabolites. Figure 2(a-c) displays a sample 
individual concentration-time profile among each CYP2B6 genotype, showing adequate 
model-prediction of the 3 compounds. The predicted versus observed concentrations of EFV 
and its major metabolites (Supplemental Figure 1) displays an even distribution of the 
observations around the linearity line indicating adequate model predictions.
The VPCs were generated as described using both the base structural model (data not 
presented) and the final covariate model for both study phases. The covariate model 
improved the prediction of EFV and 8-OH EFV, while 7-OH EFV was adequately predicted 
in both models in the absence (Figure 3) and presence of clopidogrel (Supplemental Figure 
2). Most of the observed concentrations are within the displayed 90% prediction interval 
(5th-95th percentiles) and symmetrically distributed around the median indicating good 
model predictive performance.
Population Simulations
Covariate model-based simulations (n= 1000 per CYP2B6 genotype group) was performed 
considering EFV autoinduction. Model-predicted EFV steady-state was CYP2B6-dependent. 
Figure 4 displays the predicted EFV concentration 14 hours following the daily dosing of 
600, 400, or 200 mg to steady-state (median, 95% prediction intervals). A daily dose of 600 
mg achieved median steady-state concentrations at 14 hours following EFV administration 
that exceeded 4 mg/L among subjects homozygous for the CYP2B6*6 allele. Carriers of the 
CYP6*1/*1 and CYP2B6*1/*6 alleles achieved concentrations where the upper bounds of 
the 95% prediction interval exceed 4 mg/L during the first 2 weeks. However, due to the 
expected autoinduction, the upper boundaries of the 95% prediction interval did not exceed 
concentrations of 4 mg/L following 2 weeks of dosing. Daily dosing of 200 and 400 mg of 
EFV did not achieve median steady-state concentrations that exceeded 4 mg/L among all 
CYP2B6 genotypes. However, CYP6*1/*1 and CYP2B6*1/*6 genotyped subjects may be at 
a risk of viral resistance and virological failure due to the predicted low exposure.
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DISCUSSION
In the present study, a pharmacogenetic-based pharmacokinetic model that describes EFV 
metabolism and disposition was developed. This is the first comprehensive model to include 
EFV and the hydroxyl metabolites in a population pharmacokinetic analysis using 
pharmacogenetic information from major elimination and disposition pathways. The 
development of this model enabled the characterization of EFV metabolic clearances and the 
assessment of potential patient and pharmacogenetic covariates on individual clearance 
pathways and other pharmacokinetic parameters. Model-based population simulations 
suggest that steady-state concentrations are dependent on CYP2B6 function and a dose 
reduction may be appropriate to avoid toxicity among patients with the CYP2B6 *6*6 
genotype.
The role that the CYP2B6*6 allele or the SNP tagging this allele (CYP2B6 516 G>T) plays 
in EFV clearance and response has been repeatedly demonstrated in vitro and in vivo in 
healthy volunteers and HIV patients. However, data on the impact of this variant on specific 
metabolic pathways of EFV are generally limited to in vitro9,10 or to single time point 
sampling.17,36 Metabolite information was incorporated into the modeling procedure in this 
study to increase the sensitivity to identifying predictors of the minor elimination pathways 
in humans. The present findings which incorporated full pharmacokinetics of EFV and 
metabolites for the first time support that: the model-estimated formation of 8-OH EFV 
represented 60 to 80% of EFV total clearance in slow (*6*6) and normal (*1*1) 
metabolizers, respectively; and the covariate analysis in the current study concurred with 
previous studies that CYP2B6 genotype is an independent predictor of EFV clearance. 
These findings confirm that EFV 8-hydroxylation represents its main clearance pathway8 
and that this pathway is mainly catalyzed by CYP2B6 in vivo and in vitro.5,6 Previous in 
vitro studies have suggested that other CYPs such as CYP2A6, CYP3A and CYP1A2 
catalyze EFV 8-hydroxylation.5,6,10 The present study which identify no effect of variants in 
these genes on EFV 8-hydroxylation indicate limited roles of CYP3A5 and CYP2A6 on this 
pathway.
In vitro microsomal studies have shown that the formation of 7-OH EFV is exclusively 
mediated by CYP2A6,6,10 representing 22.5% of EFV total metabolism.6 These findings are 
consistent with the current study where the formation of 7-OH EFV represented 
approximately 20% of total elimination. The additional pathway, which is estimated to be 
less than 5% of the total elimination in this study, may represent EFV N-glucuronidation by 
UGT2B7.7,17 The current analysis did not identify CYP2A6 genetic variations as significant 
covariates in the final model for EFV 7-hydroxylation. Formation of 7-hydroxylation was 
confirmed in vivo17 and genetic variants in the CYP2A6 have been associated with 7-OH 
EFV formation,17 or EFV exposure by some investigators,17–20 while other authors did not 
find any statistically significant association.37,38 Taken together with the current results, the 
contribution of CYP2A6-mediated 7-hydroxylation to the overall elimination of EFV is 
likely to be small.
Eleven of the subjects in this study were classified as CYP3A5 non-expressers (Table 1). 
Stepwise development of the covariate model showed potential influence of CYP3A5 on the 
Abdelhady et al. Page 8
J Clin Pharmacol. Author manuscript; available in PMC 2015 April 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
formation of 8-OH EFV (Supplemental Table 1). However, this influence lost statistical 
significance when CYP2B6 was incorporated as a variable and thus, did not add further 
contribution into the variability beyond CYP2B6. However, this analysis may be 
confounded as five out of the six CYP2B6 slow metabolizers had the CYP3A5 non-
expressers status. This overlap may explain the lack of an additive contribution of CYP3A5 
in EFV since all of the CYP2B6 slow metabolizer also possessed decreased CYP3A5 
function.
In one study, CYP2A6 and CYP3A4 have been reported to influence on EFV total clearance 
when CYP2B6 is impaired.18 In that study, a pharmacogenetic model was developed, where 
a joint effect of CYP2B6 together with either CYP2A6 or 3A4 was significant in some 
individuals with genetically reduced CYP2B6 function. Consequently, modeling was 
performed in the presence and absence of CYP2B6 inhibition with clopidogrel to enhance 
the potential minor metabolic pathways (i.e. CYP2A6 and CYP3A5). The goal was to 
reduce the influence of CYP2B6 function on 8-OH formation. However, neither CYP2A6 
nor CYP3A5 were independent predictors of EFV metabolite formation. This may be in part 
attributed to the properties of clopidogrel where only a 22% and 19% reduction in the 
formation and elimination of 8-OH EFV was observed. Overall, it is possible that CYP2A6 
and CYP3A5 have a minor contribution to EFV elimination in humans. This suggestion is 
supported by a recent genome-wide association study (GWAS) demonstrating that only 
CYP2B6 variants reached a genome wide significance level.37
The influence of MDR1 genotype on EFV pharmacokinetics has been controversial. A 
retrospective analysis on 43 EFV-treated patients displayed no effect of MDR1 C3435T on 
EFV plasma concentrations.26 Additionally, no association was reported between MDR1 
polymorphisms at positions 2677 or 3435 and EFV pharmacokinetics.25 However, a recent 
study showed a 26% increase in EFV bioavailability in Ugandans individuals homozygous 
for ABCB1 A4036G polymorphism.28 In the present study, subjects were genotyped for 
MDR1 polymorphisms at position 2677 and 3435. Neither of the polymorphisms were 
significant predictors of EFV pharmacokinetics in our study. The reason for the discrepancy 
remains unclear, but the possibility that ethnic and racial differences in study population 
contribute to this cannot be excluded.
The final model was utilized to predict the influence of CYP2B6 on EFV exposure. It has 
been reported that the clearance of EFV may be decreased with prolonged exposure due to 
an induction of its own metabolism.21–24 Consequently, our model-based simulations were 
performed in the presence of EFV inducing its own metabolism (i.e. auto-induction). 
Homozygous subjects of CYP2B6*6 allele displayed approximately a 30% reduction in the 
total EFV clearance which was evident in the simulated steady-concentrations. Following a 
600 mg daily dose, both normal and intermediate metabolizers achieved similar simulated 
steady state EFV concentrations, while slow metabolizers (CYP2B6*6 homozygous) 
achieved higher simulated steady state at median of 8 mg/L. These simulated concentrations 
suggest differential auto-induction in the different genotypes and that there may be a higher 
incidence of adverse effects (e.g., CNS and hepatotoxicity) in slow metabolizers.
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It has been reported that the incidence of adverse events is higher in patients with EFV 
steady state concentrations exceeding 4mg/L, while therapeutic failure may occur at steady 
state concentrations below 1mg/L.3 Consequently, simulations were performed using 
reduced doses of 200 mg and 400 mg daily. The model-based simulations showed that 200-–
00mg daily doses maintained the steady state concentration of EFV between 1 and 4 mg/L in 
subjects with the CYP2B6*6/*6 genotype (i.e. slow metabolizer). These simulations require 
further validation using multiple dosing study design that enables genotype-based modeling 
of EFV steady-state.
In summary, a pharmacogenetic-based covariate model has been developed to characterize 
and quantify EFV elimination pathways. CYP3A5 and CYP2B6 explained the variability in 
EFV concentrations and predicted the 8-OH formation in the univariate analysis. However, 
only CYP2B6 genotype predicted EFV pharmacokinetics and exposure in the multivariate 
analysis. One limitation of our study is the small sample size that might have precluded firm 
conclusions on the subtle contribution of accessory pathways on EFV disposition. Model 
based simulations warrant the prospective validation that daily doses of EFV 200 mg and 
400 mg among CYP2B6 slow metabolizers will maintain antiviral efficacy while decreasing 
adverse events. Additionally, the developed pharmacogenetic model will allow further 
evaluation of dose-reduction recommendations in CYP2B6 slow metabolizers, as has been 
suggested.31,33,39,40
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Figure 1. 
Structural model describing disposition of EFV and its major metabolites, following first 
order oral absorption from the GIT with delay represented by Ka , the first order absorption 
rate constant, tlag is the absorption lag time. EFV is characterized by two-compartment 
model; central and peripheral and it is eliminated from central compartment by non-
metabolic clearance (CLother/F) and the metabolic transformation into 7-OH EFV (CLf1/F) 
and 8-OH EFV (CLf2/F). Both metabolites are characterized by one-compartment each with 
linear clearance (CLm1, CLm2). Q/F is EFV distribution clearance, and V is the volume of 
distribution of the annotated compartments.
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Figure 2. 
Representative individual observed concentration-time profiles in individuals representing 
CYP2B6 genotypes, (a) *1/*1, (b) *1/*6, (c) *6/*6 of EFV (●), 7-OH EFV (△), and 8-OH 
EFV (□). Solid lines represent the final model-predicted concentrations of each compound.
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Figure 3. 
Visual predictive checks of (a) EFV, (b) 7-OH EFV, and (c) 8-OH EFV based on 1000 
simulations per each CYP2B6 genotype group following a 200 mg dose of EFV. Dashed 
lines represent the 5th and 95th percentiles while the solid line is the median of simulated 
plasma concentrations.
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Figure 4. 
Efavirenz simulated plasma concentration at 14 hours following administration of a) 600, b) 
400, and c) 200 mg daily. Median and 95% prediction interval of simulated concentrations 
are displayed for each CYP2B6 genotype; Dark Gray (*1/*1), Light Gray (*1/*6) and Whtie 
(*6/*6).
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Table 1
Study population demographics
Characteristics Mean (SD)
Height (m) 1.73 (0.04)
Body Weight (Kg) 70.9 (7.7)
Body Mass Index (Kg/m2) 23.5 (2.4)
CYP2A6 n (%)
 *1/*1 5 Normal 5 (29.4%)
 *1/*7 1
Intermediate 6 (35.3%)
 *1/*9 5
 *1/*4 3
Slow 6 (35.3%)
 *1/*15 1
 *9/*9 1
 *9/*15 1
CYP2B6
 *1/*1 6 (35.3%)
 *1/*6 6 (35.3%)
 *6/*6 5 (29.4%)
CYP3A5
 *1/*1 2 (11.8%)
 *1/*3 4 (23.5%)
 *3/*3 11 (64.7%)
MDR1 2577G/A/T
 GG 5 (29.4%)
 GA 3 (17.6%)
 GT 3 (17.6%)
 AA 1 (5.8%)
 TT 3 (17.6%)
 TA 2 (11.8%)
MDR1 3435C/T
 CC 12 (70.6)
 CT 3 (17.6%)
 TT 2 (11.8%)
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